Despite the global financial crisis leaders in the war on AIDS have pleaded for financial support from donors. They have warned that retreat would imperil hard-won progress to provide drugs and craft a vaccine against HIV.
"The financial crisis is of course affecting, and clearly affecting, the capacity of donors to fund international programs on AIDS," said Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Advertisement
Michel Kazatchkine, executive director of the Global Fund to fight AIDS, attends a press conference in Paris in 2008
An Afghan HIV patient sits during the opening of the first Ante-Retroviral Treatment (ART) center in Kabul on April 2009
Speaking to journalists at the start of a four-day scientific congress on AIDS vaccines, Kazatchkine said he was worried about donor retrenchment next year, when a three-year round of fund-raising comes to an end.
"2010 will be a key year when it comes to funding global health and funding AIDS prevention, treatment and AIDS science," he said.
"The risk is... that we lose the momentum, that we lose the trust and that we lose the hope that we have generated in an unprecedented movement in global health in the last eight years."
![AIDS/HIV - Clinical Features]( "AIDS/HIV - Clinical Features")
Encyclopedia section of medindia gives general info about HIV Clinical Features
Peter Piot, former chief of the UN agency UNAIDS and now head of the Institute for Global Health in London, said he was "very worried... that attention for the AIDS response in general is fading."
"It's very ironic, (in) that it comes at a time when we have real results -- four million people on anti-retroviral therapy in lower and middle income countries (and) achievement in HIV prevention."
Piot added: "Now is not the time to decrease efforts, because the bill is then going to get higher and higher. It's a matter of 'pay now or pay later.' We know that there is money... The bailout of banks has shown that there is money, there is mega-money when it is needed."
The Paris conference, gathering around 1,000 scientists, comes on the back of the first glimmer of hope in a quarter-century quest for a vaccine against the human immunodeficiency virus (HIV).
On September 24, Thai and US researchers reported that a prototype vaccine tested among 16,000 volunteers reduced the risk of HIV infection by nearly a third.
The data was due to be scrutinised in Paris on Tuesday for the first time in a scientific arena.
Meanwhile, a Swedish researcher on Monday reported that a vaccine tested on a small scale in Tanzania may provide better protection than the Thai formula.
"We hope that our vaccine could increase protection to 50 percent," Britta Wahren, a professor emeritus at Sweden's Karolinska Institute, told AFP.
The Swedish vaccine, called Hivis, was tested on 60 healthy policemen in Tanzania in what is called a Phase II study. The data is to be presented in Paris on Wednesday.
Several experts questioned at the conference on Monday reiterated their view that the apparent protection offered by the Thai vaccine was too low to be considered an effective shield against HIV.
They also declined to comment on the Swedish vaccine until they had seen the results.
"We need to see the data and discuss it and evaluate it," said Alan Bernstein, executive director of the Global HIV Vaccine Enterprise.
He added, though, "We're meeting at an important landmark moment in HIV vaccine research... today, HIV vaccine research is moving faster than at any time in the last 26 years."
Source: AFP
RAS
"The risk is... that we lose the momentum, that we lose the trust and that we lose the hope that we have generated in an unprecedented movement in global health in the last eight years."
AIDS/HIV - Clinical Features
Encyclopedia section of medindia gives general info about HIV Clinical Features
Advertisement
Peter Piot, former chief of the UN agency UNAIDS and now head of the Institute for Global Health in London, said he was "very worried... that attention for the AIDS response in general is fading."
"It's very ironic, (in) that it comes at a time when we have real results -- four million people on anti-retroviral therapy in lower and middle income countries (and) achievement in HIV prevention."
Piot added: "Now is not the time to decrease efforts, because the bill is then going to get higher and higher. It's a matter of 'pay now or pay later.' We know that there is money... The bailout of banks has shown that there is money, there is mega-money when it is needed."
The Paris conference, gathering around 1,000 scientists, comes on the back of the first glimmer of hope in a quarter-century quest for a vaccine against the human immunodeficiency virus (HIV).
On September 24, Thai and US researchers reported that a prototype vaccine tested among 16,000 volunteers reduced the risk of HIV infection by nearly a third.
The data was due to be scrutinised in Paris on Tuesday for the first time in a scientific arena.
Meanwhile, a Swedish researcher on Monday reported that a vaccine tested on a small scale in Tanzania may provide better protection than the Thai formula.
"We hope that our vaccine could increase protection to 50 percent," Britta Wahren, a professor emeritus at Sweden's Karolinska Institute, told AFP.
The Swedish vaccine, called Hivis, was tested on 60 healthy policemen in Tanzania in what is called a Phase II study. The data is to be presented in Paris on Wednesday.
Several experts questioned at the conference on Monday reiterated their view that the apparent protection offered by the Thai vaccine was too low to be considered an effective shield against HIV.
They also declined to comment on the Swedish vaccine until they had seen the results.
"We need to see the data and discuss it and evaluate it," said Alan Bernstein, executive director of the Global HIV Vaccine Enterprise.
He added, though, "We're meeting at an important landmark moment in HIV vaccine research... today, HIV vaccine research is moving faster than at any time in the last 26 years."
Source: AFP
RAS
AIDS/HIV - Common Opportunistic Infections
Kaposi sarcoma develops below the skin surfaces or in mucous membranes of mouth, nose or anus and appears as lumps
Advertisement
 AIDS / HIV - TreatmentEncyclopedia section of medindia explains in brief about the treatment for AIDS/HIV | Advertisement
|
Advertisement
Recommended Reading
Latest AIDS/HIV News
A new study has found that the co-localization of tuberculosis disease and HIV in lymphatic tissues leads to the emergence of potent HIV antibodies.
Specific antiviral drug that is widely used to treat smallpox patients since last summer's outbreak is found to produce similar outcomes regardless of the patient's HIV status.
In susceptible communities because of poverty, and racism, the effects of inadequate STI and HIV screening may be more profound.
In India, annual HIV infections and AIDS-related deaths continue to drop. Between 2010 and 2021, new HIV infections dropped by 46%.
Globally, all countries have promised to end AIDS by 2030, for which it is essential to safeguard individuals living with HIV to complete HIV care services.